Author/Authors :
Steinberg, Amir Icahn School of Medicine at Mount Sinai - New York, USA , Van Cleave, Janet H Department of Nursing - Mount Sinai Hospital - Icahn School of Medicine at Mount Sinai - New York, USA , Parikh, Anish B Icahn School of Medicine at Mount Sinai - New York, USA , Moshier, Erin Department of Population Health Science and Policy - Icahn School of Medicine at Mount Sinai - New York, USA , Ru, Meng Department of Population Health Science and Policy - Icahn School of Medicine at Mount Sinai - New York, USA , Marks, Douglas Columbia University Medical Center - New York, USA , Montelibano, Antoinette Department of Nursing - Mount Sinai Hospital - Icahn School of Medicine at Mount Sinai - New York, USA , Philpott, Amanda Department of Nursing - Mount Sinai Hospital - Icahn School of Medicine at Mount Sinai - New York, USA , Garner, Kourtney Department of Nursing - Mount Sinai Hospital - Icahn School of Medicine at Mount Sinai - New York, USA , Hammer, Marilyn J Department of Nursing - Mount Sinai Hospital - Icahn School of Medicine at Mount Sinai - New York, USA
Abstract :
Background: Abnormal blood glucose (BG) levels during hematopoietic cell transplantation (HCT) are associated with increased infections, delayed engraftment, and prolonged hospitalization, though little is known about these associations.
Materials and Methods: We retrospectively evaluated mean BG levels in the week prior to HCT and subsequent outcomes for 852 HCTs at our hospital from 1/2009 – 12/2013 pertaining to 745 patients. Outcomes included infections (pneumonia, C. difficile, positive cultures, administration of antimicrobials, or neutropenic fever), time-to-engraftment (TTE), and quality indicators (30- and 90-day readmission rates [RR] and median length-of-stay [LOS]).
Results: We retrospectively evaluated mean BG levels in the week prior to HCT and subsequent outcomes for 852 HCTs at our hospital from 1/2009 – 12/2013 pertaining to 745 patients. Outcomes included infections (pneumonia, C. difficile, positive cultures, administration of antimicrobials, or neutropenic fever), time-to-engraftment (TTE), and quality indicators (30- and 90-day readmission rates [RR] and median length-of-stay [LOS]).
Conclusion: Pre-HCT BG trends may be a prognostic biomarker for adverse outcomes, and thus can help improve quality of care for HCT patients.
Keywords :
Glucose , Hyperglycemia , Patient readmission , Bone marrow transplant , Infection , Health resource utilization
